(Q39157923)

English

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients

scientific article published on March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients (English)

1 reference

Europe PubMed Central

9 September 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Jacob Lalezari

1

1 reference

Europe PubMed Central

9 September 2017

Gopal K Yadavalli

2

1 reference

Europe PubMed Central

9 September 2017

Michael Para

3

1 reference

Europe PubMed Central

9 September 2017

Gary Richmond

4

1 reference

Europe PubMed Central

9 September 2017

Edwin Dejesus

5

1 reference

Europe PubMed Central

9 September 2017

Stephen J Brown

6

1 reference

Europe PubMed Central

9 September 2017

Wendy Cai

7

1 reference

Europe PubMed Central

9 September 2017

Cecil Chen

8

1 reference

Europe PubMed Central

9 September 2017

John Zhong

9

1 reference

Europe PubMed Central

9 September 2017

Lu Anne Novello

10

1 reference

Europe PubMed Central

9 September 2017

Michael M Lederman

11

1 reference

Europe PubMed Central

9 September 2017

G Mani Subramanian

12

1 reference

Europe PubMed Central

9 September 2017

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

9 September 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

9 September 2017

197

1 reference

Europe PubMed Central

9 September 2017

5

1 reference

Europe PubMed Central

9 September 2017

721-727

1 reference

Europe PubMed Central

9 September 2017

Biology of CCR5 and its role in HIV infection and treatment

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Access denied? The status of co-receptor inhibition to counter HIV entry

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

HIV co-receptor inhibitors as novel class of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load

1 reference

https://api.crossref.org/works/10.1086%2F527327

21 January 2018

Identifiers

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39157923&oldid=1810841505"